Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Tuesday broker round-up

Tue, 04th Jun 2019 13:55

(Sharecast News) - NewRiver: Berenberg downgrades to hold with a target price of 248p.Royal Mail: Deutsche Bank reiterates sell with a target price of 150p.AstraZeneca: Deutsche Bank reiterates sell with a target price of 6,800p.Premier Asset Management: Liberum reiterates buy with a target price of 230p.UDG Healthcare: Peel Hunt reiterates buy with a target price of 1,165p.Chariot Oil & Gas: Peel Hunt upgrades to add with a target price of 7p.VP: Peel Hunt reiterates hold with a target price of 800p.Great Portland Estates: Goldman Sachs downgrades to sell with a target price of 585p.Royal Dutch Shell: RBC Capital Markets reiterates sector performance with a target price of 2,750p.Coca Cola: Credit Suisse reiterates outperform with a target price of 3,250p.Kenmare Resources: Berenberg reiterates hold with a target price of 2,700p.

Related Shares

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.